Recently, Fengshi Technology received RMB 30 million (approximately USD 4.11 million) in strategic funding from Shandong Finance Capital Management Co., Ltd. According to the agreement, the funds will be allocated for the comprehensive development and utilization of marine pharmaceuticals and bioproducts. Fengshi Technology specializes in the R&D of nutritional products, focusing on Antarctic krill oil and marine active lipid bioproducts. Its first product, a blue-hat-certified krill oil, demonstrated effectiveness in maintaining healthy blood lipid levels and boosting immunity during clinical trials. (Source: China Securities Journal)
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE